About Nemesis: Experts in Intelligent Biosignal Processing

Founded in 2017 and headquartered in Pangyo, South Korea, Nemesis is a global leader in semiconductor-based intelligent biosignal processing solutions. We are committed to providing medical device manufacturers with precise, customizable, and intelligent chip technologies, helping our customers develop innovative miniaturized medical devices that significantly enhance the quality of patient care.

Technical Excellence

Backed by outstanding analog and digital signal processing capabilities, Nemesis has established a strong and differentiated technological moat in the market.

Impedance Boosting:

Significantly increases input impedance, making vital sign measurement possible even without direct skin contact.

Wide Dynamic Range:

Provides an exceptionally wide input signal range, greatly improving measurement accuracy and data reliability.

Multi-Modal Interface:

A single chip can simultaneously process multiple biosignals, including EEG, ECG, EMG, and Bio-Z.

Edge Intelligence (Tiny Machine Learning):

Machine learning algorithms are integrated directly on-chip, enabling localized intelligent diagnostic functions.

Benefits of Nemesis Solutions

We address the key pain points faced by digital medical device developers through comprehensive performance optimization.

Long Battery Life:

With an ultra-low-power design, our solutions reduce the need for frequent charging in wearable medical devices.

Smaller Form Factor:

By significantly minimizing chip and circuit board size, we meet the demands of modern lightweight and compact wearable devices.

High-Level Customization Support:

We overcome the limitations often associated with major semiconductor suppliers in supporting low-volume, highly customized development, offering professional support from consultation to co-development.

Accurate Data Processing:

Our technology effectively eliminates noise interference, transforming complex biosignals into precise and clinically meaningful medical data.

Core Chip Product Portfolio (Chips Developed So Far)

The following are Nemesis’s core chip series that have been developed and brought to market to date:

NMI1000 (mass production in 2024): A programmable CDC SoC designed for image sensing and capsule endoscopy development.

NMS4110 (mass production in 2024): An electrochemical sensing ROIC primarily used in continuous glucose monitoring (CGM) and electrocardiogram (ECG) devices.

NMX3210: A programmable multi-channel capacitance-to-digital converter (CDC) specifically designed for high-precision force and torque sensing.

NMS2110: An impedance measurement chip for body composition analysis and proximity sensing applications.

Applications

Nemesis technologies have been widely adopted across a broad range of digital healthcare applications.

Diverse Biomarker Monitoring:

Including body temperature, pulse, blood pressure, blood oxygen saturation, pH, and various electrochemical analyses.

Medical Monitoring Patches:

Such as CGM glucose monitoring patches and ECG monitoring patches.

Smart Wearable Devices:

Including EEG headbands, true wireless stereo (TWS) earbuds, smartwatches, and smart bands.